Year: 2018
Type: article
Abstract: This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many diseaseconditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibroblast growth factor receptors(FGFR) tyrosine kinase inhibitor, FGF-23 antibody, FGF-23 C-terminal peptide, CYP24A1 inhibitor, and FGF-23 antagonist. Wealso update the advantages and disadvantages of targeting upstream and downstream molecules in FGF-23 signaling pathways.
Source: Nephrology - Open Journal
DOI: 10.17140/npoj-4-118
Authors: Fan Li, Zhousheng Xiao
Institution: University of Tennessee Health Science Center
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2916375737